Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics for patients, physicians, and healthcare systems in the United States. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including oligonucleotides, peptides, proteins, and antibodies. Its product pipeline includes RT-102, a parathyroid hormone that is in Phase I clinical trial for the treatment of osteoporosis; RT-105, an anti-TNF-alpha antibody that is in preclinical studies to treat psoriatic arthritis; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-111, an ustekinumab biosimilar for the treatment of various inflammatory conditions. The has a collaboration agreement with ProGen Co., Ltd. for the o-development and commercialization of RT-114 to treat obesity. Rani Therapeutics Holdings, Inc. was founded in 2012 and is headquartered in San Jose, California.

Market Cap	$197.03M	P/E Ratio	N/A
52W High	$3.87	52W Low	$0.39
Div Yield	N/A	Payout Ratio	N/A
EPS Growth 3Y	-34.7%	52W Position	27.4%
Overall Score	43	Value Score	40
Quality Score	39	Technical Score	50

EPS Current Est	$-0.37	EPS Next Est	$-0.18
EPS Growth Est	N/A	DPS Growth 3Y	N/A

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RANI	$1.34	-8.84%	3.33M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RANI	$1.34	-8.8%	3.33M
3
4
5
6

RANI

RANI

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Rani Therapeutics Holdings Inc. Data in Excel

Get Rani Therapeutics Holdings Inc. Data in Excel